Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.

@article{Hildenbrand2007ImmunotherapyOP,
  title={Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.},
  author={Bernd Hildenbrand and Birgitta Sauer and O Kalis and Claude Stoll and Marina A. Freudenberg and Gabriele Niedermann and J{\"u}rgen M Giesler and Eva Juettner and John A. Peters and Brigitte Haering and Roberto Leo and Clemens Unger and Marc Az{\'e}mar},
  journal={The Prostate},
  year={2007},
  volume={67 5},
  pages={500-8}
}
PURPOSE We conducted a pilot trial to assess the feasibility and tolerability of a prime/boost vaccine strategy using interferon-gamma (IFN-gamma) and autologous dendritic cells (DCs) pulsed with HLA-A2-specific prostate-specific antigen (PSA) peptides (PSA-1 [141-150]; PSA-2 [146-156]; PSA-3 [154-163]) for the treatment of 12 patients with hormone refractory prostate carcinoma. PATIENTS AND METHODS All patients were vaccinated four times with intracutaneously injected PSA-peptide loaded DCs… CONTINUE READING
26 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…